SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Astria Therapeutics, Inc. (ATXS) , 前瞻盈利收益率 17.42%.
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+78.9%).
- 前瞻市盈率 5.7
- 分析师共识目标价 $22.50 (+78.9% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 49/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ATXS
估值倍数
P/E (TTM)0.0
前瞻 P/E5.7
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-1.67
前瞻 EPS（预估）$2.19
每股账面价值$0.00
每股营收$0.00
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield17.42%
股息收益率0.00%
分析师目标价$22.50 (+78.9%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2015 |
$-243.45 |
$0.00 |
$-32.63M |
- |
| 2016 |
$-133.31 |
$0.00 |
$-36.06M |
- |
| 2017 |
$-75.73 |
$500K |
$-27.36M |
-5472.8% |
| 2018 |
$-30.71 |
$0.00 |
$-25.87M |
- |
| 2019 |
$-14.06 |
$0.00 |
$-26.24M |
- |
| 2020 |
$-12.12 |
$0.00 |
$-37.06M |
- |
| 2021 |
$-3.38 |
$0.00 |
$-30.17M |
- |
| 2022 |
$-3.55 |
$0.00 |
$-51.83M |
- |
| 2023 |
$-2.42 |
$0.00 |
$-72.89M |
- |
| 2024 |
$-1.67 |
$0.00 |
$-94.26M |
- |
